Nina M. Gussack - Lawyer in Philadelphia, PA

Ninas trial practice is concentrated in civil litigation, with a primary emphasis in the defense of pharmaceutical and medical device companies regarding marketed products, investigational new drugs, medical devices and over-the-counter drug products. Nina serves as national coordinating and trial counsel and as regional counsel in pharmaceutical litigation, including class actions and multi-district litigation.

Nina also represents pharmaceutical manufacturers, consultants and academic institutions in civil and criminal actions in related complex litigation involving health care fraud and abuse, and the defense of individual and class actions. She has conducted internal corporate investigations, audits and negotiations with government agencies, as counsel to pharmaceutical companies in grand jury proceedings and multistate investigations. Her practice includes counseling regarding regulatory issues governing clinical trials and compliance in promotional activities, as well as Lanham Act claims in the pharmaceutical industry.

She is the recipient of numerous awards and high national rankings from legal publications, including being named to the Top 10 Female Litigators in the United States by Benchmark Litigation, based on receiving the most robust and vocal ?best in class nominations by peers and clients. Nina also was named by the national legal newswire Law360 as one of the 10 Most Admired Product Liability Attorneys in the country, has been listed in Best Lawyers in America for Product Liability Litigation — Defendants every year since 2013, and was honored by LMG Life Sciences as Life Sciences Lawyer of the Year in 2015. She also is a member of the LMG Life Sciences Hall of Fame and has been selected as a Life Sciences Star by LMG Life Sciences every year since 2012.

Nina is a frequent writer and lecturer on medical, pharmaceutical and medical device issues, and has given presentations at ACI, PhRMA, DRI, Drug Information Association (DIA), Food and Drug Law Institute (FDLI) and American Law Institute-American Bar Association (ALI-ABA) programs on fraud and abuse issues, federal preemption, off-label promotion, minimizing civil liability risks during pendency of a government investigation, clinical trials, Daubert challenges, informed consent, and risk management in the pharmaceutical industry. She also is a member of the Steering Committee of the Emory Law Institute for Complex Litigation and Mass Tort Claims, which supports the judiciary and the bar by advancing the understanding of new developments and trends in the resolution of mass claims within and outside of litigation.